Status:
COMPLETED
Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan
Lead Sponsor:
University of Aarhus
Conditions:
Kidney Failure, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Angiotensin II receptor blockers (ARB) are known to preserve kidney function among patients with kidney diseases and reduced renal function, but not among haemodialysis patients. Haemodialysis patien...
Detailed Description
Haemodialysis patients often lose residual renal function rather quickly after initiation of dialysis - average loss is 30 % per year. Loss of residual kidney function leads to deteriorating quality o...
Eligibility Criteria
Inclusion
- Haemodialysis patient
- Haemodialysis treatment for maximum 12 months
- \> 18 years old
- informed consent
- urine volume \> 300 ml / 24 hours
- contraception if fertile woman
Exclusion
- Systolic blood pressure \< 110 mm Hg
- Able to comprehend the aims of the project and follow instructions
- Allergy to irbesartan/ACE-inhibitors/ARBs
- Myocardial infarction or unstable angina pectoris during the last 3 months
- Ejection fraction \< 30 %
- Pregnancy
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT00791830
Start Date
April 1 2009
End Date
January 1 2013
Last Update
January 8 2013
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nephrology, Aarhus University, Aalborg
Aalborg, Denmark, 9000
2
Department of Nephrology, Aarhus University Hospital, Skejby
Aarhus N, Denmark, 8200
3
Department of Medicine, Fredericia Hospital
Fredericia, Denmark, 7000
4
Haemodialysis unit, Horsens Hospital
Horsens, Denmark, 8700